Mireille Guay

Bio: Mireille Guay is an academic researcher from Health Canada. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 19, co-authored 29 publications receiving 1186 citations.

Exposure to wind turbine noise: Perceptual responses and reported health effects.

Abstract: Health Canada, in collaboration with Statistics Canada, and other external experts, conducted the Community Noise and Health Study to better understand the impacts of wind turbine noise (WTN) on health and well-being. A cross-sectional epidemiological study was carried out between May and September 2013 in southwestern Ontario and Prince Edward Island on 1238 randomly selected participants (606 males, 632 females) aged 18-79 years, living between 0.25 and 11.22 km from operational wind turbines. Calculated outdoor WTN levels at the dwelling reached 46 dBA. Response rate was 78.9% and did not significantly differ across sample strata. Self-reported health effects (e.g., migraines, tinnitus, dizziness, etc.), sleep disturbance, sleep disorders, quality of life, and perceived stress were not related to WTN levels. Visual and auditory perception of wind turbines as reported by respondents increased significantly with increasing WTN levels as did high annoyance toward several wind turbine features, including the following: noise, blinking lights, shadow flicker, visual impacts, and vibrations. Concern for physical safety and closing bedroom windows to reduce WTN during sleep also increased with increasing WTN levels. Other sample characteristics are discussed in relation to WTN levels. Beyond annoyance, results do not support an association between exposure to WTN up to 46 dBA and the evaluated health-related endpoints.

Indoor air quality and the risk of lower respiratory tract infections in young Canadian Inuit children

Abstract: Background: Inuit infants have the highest reported rate of hospital admissions because of lower respiratory tract infections in the world. We evaluated the prevalence of reduced ventilation in houses in Nunavut, Canada, and whether this was associated with an increased risk of these infections among young Inuit children. Methods: We measured ventilation in 49 homes of Inuit children less than 5 years of age in Qikiqtaaluk (Baffin) Region, Nunavut. We identified the occurrence of lower respiratory tract infections using a standardized questionnaire. Associations between ventilation measures and lower respiratory tract infection were evaluated using multiple logistic regression models. Results: The mean number of occupants per house was 6.1 people. The mean ventilation rate per person was 5.6 L/s (standard deviation [SD] 3.7); 80% (37/46) of the houses had ventilation rates below the recommended rate of 7.5 L/s per person. The mean indoor carbon dioxide (CO 2 ) concentration of 1358 (SD 531) ppm was higher than the recommended target level of 1000 ppm. Smokers were present in 46 homes (94%). Of the 49 children, 27 (55%) had a reported history of lower respiratory tract infection. Reported respiratory infection was significantly associated with mean CO 2 levels (odds ratio [OR] 2.85 per 500-ppm increase in mean indoor CO 2 , 95% confidence interval [CI] 1.23–6.59) and occupancy (OR 1.81 for each additional occupant, 95% CI 1.14–2.86). Interpretation: Reduced ventilation and crowding may contribute to the observed excess of lower respiratory tract infection among young Inuit children. The benefits of measures to reduce indoor smoking and occupancy rates and to increase ventilation should be studied.

Formaldehyde in the Indoor Environment

Abstract: 1.1. History Formaldehyde was described in the year 1855 by the Russian scientist Alexander Michailowitsch Butlerow. The technical synthesis by dehydration of methanol was achieved in 1867 by the German chemist August Wilhelm von Hofmann. The versatility that makes it suitable for use in various industrial applications was soon discovered, and the compound was one of the first to be indexed by Chemical Abstracts Service (CAS). In 1944, Walker published the first edition of his classic work Formaldehyde.(1) Between 1900 and 1930, formaldehyde-based resins became important adhesives for wood and wood composites. The first commercial particle board was produced during World War II in Bremen, Germany. Since 1950, particle board has become an attractive alternative to solid wood for the manufacturing of furniture. Particle board and other wood-based panels were subsequently also used for the construction of housing. Adverse health effects from exposure to formaldehyde in prefabricated houses, especially irritation of the eyes and upper airways, were first reported in the mid-1960s. Formaldehyde emissions from particle boards bonded with urea formaldehyde resin were soon identified as the cause of the complaints. As a consequence, a guideline value of 0.1 ppm was proposed in 1977 by the former German Federal Agency of Health to limit human exposure in dwellings. Criteria for the limitation and regulation of formaldehyde emissions from wood-based materials were established in 1981 in Germany and Denmark. The first regulations followed in the United States in 1985 or thereabouts. In Germany and the United States, large-scale test chambers were used for the evaluation of emissions. Although the chamber method is very reliable, it is also time-consuming and expensive. This meant there was a strong demand for simple laboratory test methods.(2)

Respiratory and Allergic Health Effects of Dampness, Mold, and Dampness-Related Agents: A Review of the Epidemiologic Evidence

Abstract: ObjectivesMany studies have shown consistent associations between evident indoor dampness or mold and respiratory or allergic health effects, but causal links remain unclear. Findings on measured m...

A Review of Biomonitoring of Phthalate Exposures

Abstract: Phthalates (diesters of phthalic acid) are widely used as plasticizers and additives in many consumer products. Laboratory animal studies have reported the endocrine-disrupting and reproductive effects of phthalates, and human exposure to this class of chemicals is a concern. Several phthalates have been recognized as substances of high concern. Human exposure to phthalates occurs mainly via dietary sources, dermal absorption, and air inhalation. Phthalates are excreted as conjugated monoesters in urine, and some phthalates, such as di-2-ethylhexyl phthalate (DEHP), undergo secondary metabolism, including oxidative transformation, prior to urinary excretion. The occurrence of phthalates and their metabolites in urine, serum, breast milk, and semen has been widely reported. Urine has been the preferred matrix in human biomonitoring studies, and concentrations on the order of several tens to hundreds of nanograms per milliliter have been reported for several phthalate metabolites. Metabolites of diethyl phthalate (DEP), dibutyl- (DBP) and diisobutyl- (DiBP) phthalates, and DEHP were the most abundant compounds measured in urine. Temporal trends in phthalate exposures varied among countries. In the United States (US), DEHP exposure has declined since 2005, whereas DiNP exposure has increased. In China, DEHP exposure has increased since 2000. For many phthalates, exposures in children are higher than those in adults. Human epidemiological studies have shown a significant association between phthalate exposures and adverse reproductive outcomes in women and men, type II diabetes and insulin resistance, overweight/obesity, allergy, and asthma. This review compiles biomonitoring studies of phthalates and exposure doses to assess health risks from phthalate exposures in populations across the globe.